

A one year open label assessment of the use of nabilone in the treatment of chronic neuropathic pain

Submission date 23/07/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/09/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 28/11/2019	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English Summary

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Dilip Kapur

Contact details

Flinders Medical Centre
Pain Management Centre
Bedford Park
Adelaide
Australia
5042
+61 8 82045499
dilip.kapur@flinders.edu.au

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

A one year open label assessment of the use of nabilone in the treatment of chronic neuropathic pain

Study hypothesis

The purpose of the study is to investigate the following:

1. Reported levels of pain in patients receiving nabilone for the treatment of chronic neuropathic pain for a period of one year
2. Patient tolerance of nabilone when used in the treatment of chronic neuropathic pain over a period of one year
3. Effects of nabilone on memory and psychometric function when used in the treatment of chronic neuropathic pain over a period of one year

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. South Tees Local Research Ethics Committee on the 26th March 2002 (ref: 00/51)
2. West Ethics Committee Glasgow on the 7th December 2001 (ref: 01/182)
3. Newcastle and North Tyneside Joint Ethics Committee on the 30th October 2001 (ref: 2000/138)

Study design

One year open label non-randomised uncontrolled trial

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Condition

Mixed neuropathic pain

Interventions

Coming out of the cross-over trial mentioned in the inclusion criteria, patients with benefit on either of the study drugs was offered to participate in the open label trial. Nabilone capsules for oral intake were titrated in the first four weeks to 1 mg, then doubled to 2 mg if there were no

side effects and then doubled again to 4 mg which was the maximum dose. The dose was then reduced to the lowest effective dose and the patient continued on this dose for one year if they did not decide to withdraw.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Nabilone

Primary outcome measure

Mean monthly pain scores compared to baseline: Visual Analogue Scale (VAS) scores were recorded daily in a diary together with hours slept and sleep interruption. Pain score were averaged over one month and compared to baseline every three months in the analysis.

Secondary outcome measures

1. Sleep was measured as hours slept and if the sleep was interrupted or not in the diary
2. Depression and anxiety were measured with the Hospital Anxiety and Depression Score (HAD) at baseline and then every three months
3. Depression
4. Quality of life was measured with the 36-item Short Form questionnaire (SF-36) at baseline and then every three months
5. Side effects were collected monthly with the eight-point questionnaire rating the severity of the side effects on a five point scale plus a field for open comments
6. Psychometric tests performed every three months

Overall study start date

01/10/2001

Overall study end date

01/01/2003

Eligibility**Participant inclusion criteria**

Patients with chronic neuropathic pain who have previously participated in the trial entitled: 'A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain' (see ISRCTN15330757) may enter this study. As such, patients will already have satisfied criteria for the diagnosis of chronic neuropathic pain.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

90

Participant exclusion criteria

Patients may not enter the study if they have a history of any of the following conditions:

1. Epilepsy
2. Liver disease
3. Psychosis
4. Bipolar disorder
5. Substance misuse
6. Renal failure
7. Adverse reactions to nabilone
8. Pregnant women, lactating women or women of childbearing potential not using effective methods of contraception
9. Patients involved in ongoing legal action against a third party in which financial compensation is being sought for personal injury alleged to be the cause of the presenting condition

Excluded medication:

Patients may not take the following medications during the study:

1. Antipsychotic drugs
2. Benzodiazepine drugs (excepting stable doses of night-time sedatives)
3. Monoamine oxidase inhibitors

Patients taking cannabinoid preparations of any kind may not be included in the study.

Recruitment start date

01/10/2001

Recruitment end date

01/01/2003

Locations**Countries of recruitment**

Australia

United Kingdom

Study participating centre

Flinders Medical Centre

Adelaide

Australia

5042

Sponsor information

Organisation

Cambridge Laboratories Ltd (UK)

Sponsor details

Deltic House Newcastle
Kingfisher Way
Silverlink Business Park
Wallsend
United Kingdom
NE28 9NX

Sponsor type

Industry

Website

<http://www.camb-labs.com/index.html>

ROR

<https://ror.org/001zd1d95>

Funder(s)

Funder type

Industry

Funder Name

Cambridge Laboratories Ltd (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration